Cooley and Freshfields Bruckhaus Deringer, together with Chinese counsel AllBright Law Offices and RuiMin Law Firm alongside Cayman law advisors Maples Group and Harney Westwood & Riegels, are advising on Anglo-Swedish pharmaceutical company AstraZeneca’s $1.2 billion acquisition of Nasdaq-listed Chinese cell therapy developer Gracell Biotechnologies.
AstraZeneca, one of the biggest drugmakers in China according to Reuters, has entered into a definitive agreement to acquire Gracell, a China-based developer of innovative cell therapies for the treatment of cancer and autoimmune diseases.
